Orchestra BioMed (OBIO) CFO Reports RSU Withholding of 16,102 Shares

Rhea-AI Filing Summary

Andrew Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc. (OBIO) reported a non‑derivative transaction on 09/17/2025 reflecting the withholding of 16,102 common shares at an effective price of $2.46 to satisfy tax withholding obligations associated with the vesting of restricted stock units. The filing shows 466,686 shares remain beneficially owned after the withholding. The Form 4 was signed by the reporting person on 09/19/2025. The disclosure notes that no shares were sold in the market as part of the tax withholding.

Positive

• Insider retains substantial ownership: reporting person holds 466,686 shares after the withholding, indicating continued stake alignment.

Negative

• Reduction in beneficial holdings: 16,102 shares were disposed of via withholding to satisfy taxes related to RSU vesting.

Insights

Corporate Governance Expert

TL;DR: Routine tax withholding on vested RSUs; no open‑market sale and insider still holds substantial shares.

The reported transaction is a common administrative event: restricted stock units vested and the issuer withheld 16,102 shares to cover tax obligations. The filing explicitly states no market sales occurred, which means there was no immediate change in supply from insider selling. The reporting officer retains 466,686 shares post‑transaction, indicating continued insider alignment with shareholders. This item is non‑material from a governance perspective absent other context.

Financial Analyst

TL;DR: Withholding reduced beneficial holdings by a discrete amount; transaction appears routine and not market moving.

Financially, the transaction shows a disposition of 16,102 shares at an indicated price of $2.46 for tax purposes related to RSU vesting. The filing specifies the shares were withheld rather than sold on the open market, limiting any immediate market impact. Without additional context on total outstanding shares or recent insider trends, this report is a routine equity compensation tax action rather than a signal of strategic change.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Andrew Lawrence

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	09/17/2025		F(1)		16,102	D	$2.46	466,686	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations.

	/s/ Andrew Taylor	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OBIO CFO Andrew Taylor report on Form 4?

He reported the withholding of 16,102 common shares to satisfy tax obligations from RSU vesting; no market sale occurred.

When was the transaction and filing dated for OBIO Form 4?

The transaction date was 09/17/2025 and the Form 4 was signed on 09/19/2025.

How many OBIO shares does the reporting person own after the transaction?

The filing shows 466,686 shares beneficially owned following the reported withholding.

At what price were the withheld OBIO shares recorded?

The shares were recorded at an effective price of $2.46 in the Form 4.

Was there an open‑market sale associated with the Form 4 transaction?

No. The document states no shares were sold in the market; the disposition was for tax withholding on vested RSUs.